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Infective endocarditis, a serious infection of the endo-
cardium of the heart, particularly the heart valves, is asso-
ciated with a high degree of illness and death. It generally
occurs in patients with altered and abnormal heart architec-
ture, in combination with exposure to bacteria through trau-
ma and other potentially high-risk activities involving
transient bacteremia. Knowledge about the origins of endo-
carditis stems from the work of Fernel in the early 1500s,
and yet this infection still presents physicians with major
diagnostic and management dilemmas. Endocarditis is
caused by a variety of bacteria and fungi, as well as emerg-
ing infectious agents, including Tropheryma whipplei,
Bartonella spp., and Rickettsia spp. We review the evolu-
tion of endocarditis and compare its progression with dis-
coveries in microbiology, science, and medicine. 
E
ndocarditis is a noncontagious chronic infection of
the valves or lining of the heart, mainly caused by
bacteria, although fungi can also be associated with this
infection (1). The risk of infection of heart valves in per-
sons predisposed to acquiring infective endocarditis
increases with the following conditions: congenital heart
disease, rheumatic fever, major dental treatment, open
heart surgery, and genitourinary procedures. New evi-
dence is growing that changes in social behavior, such as
an increase in the incidence of body piercing, excessive
alcohol consumption, and the use of intravenous self-
administered illicit drugs may also predispose a suscepti-
ble person to an increased risk of acquiring endocarditis.
The patient may exhibit any of the following signs and
symptoms: fatigue and weakness; weight loss; fever and
chills; night sweats; heart murmur; aches and pains;
painful nodes in the pads of fingers and toes; red spots on
skin of palms and soles; nail abnormalities; swelling of
feet, legs, and abdomen; shortness of breath with activity;
and blood in the urine. A medical history, physical exam-
ination, and echocardiogram are usually performed.
Blood samples are usually taken, and the physical and
biochemical properties of the blood are investigated.
Endocarditis is usually curable provided an early diagno-
sis is made, and the patient receives the appropriate
antimicrobial treatment; the time needed for recovery is
approximately 6–8 weeks. The patient generally requires
long-term antimicrobial drugs (4–6 weeks), hospitaliza-
tion, and in some cases, valve replacement. A number of
complications may be associated with the disease such as
blood clots, stroke, heart rhythm problems, abscesses, and
other infections. Infective endocarditis is associated with
severe illness and death and generally occurs in patients
with altered and abnormal heart architecture who have
been exposed to bacteria through trauma and other poten-
tially high-risk activities. 
In 1885, Sir William Osler presented three Gulstonian
Lectures on the topic of malignant endocarditis, which
gave a comprehensive account of the disease and outlined
the difficulties in its diagnosis (2). The disease had, in fact,
been described by a French Renaissance physician, Jean
François Fernel, approximately 350 years previously (3).
More than 100 years after Osler’s lectures, this serious
infection can still remain a diagnostic and therapeutic
dilemma. Its name has been changed several times, first to
“bacterial endocarditis” and subsequently to “infective
endocarditis” after the observation that microbiologic
agents other than bacteria may cause the disease. In the
early years of the new millennium, infective endocarditis
still proves to be difficult to diagnose and is associated
with a high death rate (21%–35%). Although many devel-
opments have taken place with respect to antimicrobial
drug therapy in the treatment of the disease, its incidence
is continuing to rise, with 3.3 cases per100,000 population
per year in the United Kingdom, with similar figures for
the United States and 1.4–4.0 cases per100,000 population
per year in Europe as a whole (4). The reasons for this rise
are the following: 1) longer survival of patients with
degenerative heart diseases, 2) increased use of antibiotics,
3) increased incidence of prosthetic heart valves, 4) con-
genital heart disease in younger children, 5) increase in
bicuspid valve disease, 6) advances in medical and surgi-
cal treatments, 7) increase in the number of injection drug
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Generally, the incidence is higher in men than in women
(2:1), and the average age group affected is in the fifth
decade (2).
Historical Perspective
A historical description of developments in endocardi-
tis closely reflects concurrent developments in laboratory
medicine, particularly microbiology. Much of the innova-
tions and developments relating to infective endocarditis
were made by physicians in Europe, particularly in France
(Appendix). Important contributions were, however, made
by several German physicians, particularly in association
with the birth of bacteriology (Appendix). More recently,
the United States has played a strong role in helping define
guidelines and diagnostic criteria that facilitate diagnosing
infective endocarditis, including the Beth Israel (5), Duke
(6) (Table 1), and modified Duke criteria (7,8) (Table 2). In
addition, the American Heart Association has published
several seminal articles on the antibiotic treatment and pre-
vention of infective endocarditis (9). 
For approximately the first 200 years after the disease
was initially described, the anatomy of the heart and heart
valves in the diseased state of infective endocarditis was
comprehensively elucidated in medical anatomical sketch-
es made after postmortem examination. (For a comprehen-
sive account of the early description of endocarditis, see
Contrepois [10].) Not until the early to mid-1800s were
descriptions recorded of the medical signs and symptoms
of the disease in live patients. Such descriptions included
the detection of cardiac murmurs, after percussion and aus-
cultation. Detection of such murmurs was aided by the
development of the stethoscope in 1816. From 1830 to
1840, elevated body temperature was recorded as an
important symptom of the disease. However, not until the
late 1800s and early 1900s was a comprehensive synthesis
of information formed by various scholars in Europe and
North America, including Sir William Osler in Canada (2)
and Thomas Horder in England (11) (Appendix). Osler and
Horder were instrumental in establishing fundamental
mechanisms regarding the pathophysiology of infective
endocarditis and are, to a large degree, responsible for how
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Table 1. Original Duke criteria for the diagnosis and classification of infective endocarditis
a 
Major criteria  Minor criteria  Diagnosis 
1. Positive blood culture 
i) Typical organism in >2 blood cultures in the 
absence of a primary focus (Staphylococcus 
aureus, enterococci, viridans streptococci, 
Streptococcus bovis, HACEK) 
ii) Persistently positive blood culture drawn more 
than 12 h apart or all ¾ drawn at least 1 h apart 
between first and last 
1. Predisposition 
Heart condition 
Drug abuse 
1. Definite 
2 Major 
1 Major and 3 minor 
5 Minor 
pathologic/histologic findings 
2. Evidence of endocardial involvement 
i) Positive echocardiogram (TOE) 
Oscillating intracardiac mass on valve, implanted 
material or supporting structures in path of 
regurgitant jets 
Abscess 
New partial dehiscence of prosthetic valve 
ii) New valvular regurgitation 
2. Fever 
>38°C 
2. Possible 
Findings fell short of the definite but not 
rejected categories 
  3. Vascular phenomena 
Major arterial emboli 
Janeway lesions 
Septic pulmonary infarcts 
3. Rejected 
Alternate diagnosis 
Resolution of the infection with antibiotic 
therapy for <4 days  
No pathologic evidence after antibiotic 
therapy 
  4. Immunologic phenomena 
Osler’s nodes 
Roth spots 
Rheumatoid factor 
Glomerulonephritis 
 
  5. Microbiologic evidence 
Positive blood culture not meeting 
major criteria 
Positive serologic finding 
 
  6. Endocardiographic evidence 
Consistent with infective endocarditis 
but not meeting the major criteria 
 
aSource: (6); HACEK, Haemophilus aphrophilus, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella 
kingae group; TOE, transesophageal echocardiogram. we view endocarditis today. The Figure (online only; avail-
able at: http://www.cdc.gov/ncidod/EID/vol10no6/03-
0848-G..htm) and Appendix chronologically map the
history of infective endocarditis, including diagnostic
developments, treatment, and prevention, and emerging
causal agents.
The birth of bacteriology as a separate discipline of
pathology gave rise to the introduction of the important
description of microbiology in the etiology of infective
endocarditis. With the early technical innovations of
Pasteur in France in the 1880s, routine blood cultures were
introduced in the late 19th century as an important part of
laboratory investigation into the microbiologic causes of
infective endocarditis. Although causal agents of infective
endocarditis could now be detected and clearly described,
little could be achieved in terms of their eradication
because the existence of antibiotics was as yet unknown.
However, in Germany, Gerard Domagk, bacteriologist and
pathologist, was appointed as director of the I.G.
Farbenindustrie (Bayer) Laboratory for Experimental
Pathology and Bacteriology in Wuppertal in 1925.
Domagk was innovative in that he began to experiment
with dyes, looking for their possible effects against various
infections. He described the effect of prontosil red against
streptococcal infections in mice; the active component of
prontosil was later described as sulfanilamide. At approxi-
mately the same time, Sir Alexander Fleming discovered
the antibacterial effects of a secondary metabolite (peni-
cillin), produced from a filamentous fungus. Such discov-
eries were revolutionary because medicine now had an
effective means of treating bacterial infections, including
infective endocarditis, caused by a wide variety of bacter-
ial pathogens, most notably Streptococcus species. Since
wild-type pathogens had not had sufficient time to develop
resistance to these newly described antimicrobial agents,
treatment failures due to resistance were infrequent.
Fleming did observe, however, that some organisms were
resistant to penicillin and suggested that the phenomenon
be followed up. Approximately 60 years later, the marked
increase in resistance to antimicrobial agents is cause for
concern on all continents. The tangible consequence is that
clinicians may have fewer antimicrobial agents to treat
both benign and serious infections, including infective
endocarditis. To combat the threat of such a “postantibiot-
ic era,” the global pharmaceutical industry has responded
by producing novel antimicrobial agents, including the
carbapenems (imipenem and ertapenem), the oxozolidones
(linezolid), and improved antifungal agents (caspofungin
and voriconazole), which prolong antimicrobial effective-
ness before the problem of resistance evolves with such
new agents.
Over the past century, streptococci and staphylococci
have remained the main causative organisms associated
with infective endocarditis, with an increase in cases due
to staphylococci associated with injection drug users and
HIV patients. With substantial advances made in the isola-
tion and identification of microorganisms, scientists now
recognize a wide spectrum of causal organisms. Although
rare, infective endocarditis is caused by gram-negative
organisms such as the HACEK (Haemophilus aphrophilus,
Actinobacillus actinomycetemcomitans, Cardiobacterium
hominis, Eikenella corrodens,  Kingella kingae) group,
Bartonella spp., and Coxiella burnetii. More recently,
cases of fungal endocarditis have increased, particularly in
postoperative patients, injection drug users, and immuno-
compromised patients (4).
A history of rheumatic fever can serve as a risk factor
for acquiring infective endocarditis. The incidence of rheu-
matic fever, which was common as recently as a century
ago, is relatively rare today (12). This decline in the inci-
dence of rheumatic fever has not been mirrored by a pro
rata decrease in the incidence of infective endocarditis,
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Table 2. Recent suggested modifications to the Duke criteria for the diagnosis of infective endocarditis (IE)
a 
Microbiologic  Biochemical  Clinical 
Blood culture 
Bacteremia due to Staphylococcus 
aureus should be considered a major 
criterion regardless of whether the 
infection is nosocomially acquired or 
whether a removable source of 
infection is present 
Serology 
Positive for Coxiella burnetii (major 
criterion)  
Positive for Bartonella spp.  
Positive for Chlamydia spp.  
Molecular 
Evidence for the presence of bacterial 
or fungal DNA in blood or valve 
material (major criterion)  
Elevated level of CRP >100 mg/L  
Elevated ESR defined as more than one and a 
half times higher than normal, i.e. , 
>30 mm/h for patients <60 years of age  
>50 mm/h for patients >60 years of age  
Possible endocarditis now defined as one 
major and one minor criterion or three 
minor criteria  
Omission of criterion “echocardiogram 
consistent with IE but not meeting major 
criterion”  
Newly diagnosed clubbing  
Evidence of splinter hemorrhages  
Petechiae  
Microscopic hematuria (disregarded for 
patients with positive urine cultures, 
menstruating women, patients with end-
stage renal disease and patients with 
urinary catheters)  
Presence of central nonfeeding venous 
lines or peripheral venous lines (minor)  
Purpura  
aSources: (7,8); CRP, C-reactive protein; ESR, erythrocyte sedimentation rate. which suggests that additional etiologic factors are becom-
ing more important in acquiring endocarditis. 
Current Trends and Future Concerns
Although endocarditis has been documented for
approximately 450 years, the diagnostic challenges and
treatment dilemmas are as real today as they were in the
time of Fernel (3). Major advances have been made in the
diagnosis of endocarditis, in both laboratory and clinical
(imaging) parameters, but we are witnessing the emer-
gence of several newly described causal bacterial species,
such as Tropheryma whipplei and Bartonella spp., as well
as sporadic case reports of unusual and uncommon causal
organisms, including Finegoldia sp.,  Gemella spp., and
Abiotrophia defectiva. In addition, since diagnostic meth-
ods, mainly 16S rDNA polymerase chain reaction (PCR)
and sequencing, are now beginning to identify such infec-
tions, no evidence base exists to help determine effective
antimicrobial drug regimens to successfully treat endo-
carditis caused by such organisms. Furthermore, as speci-
mens from many of these infections are culture-negative,
conventional antibiotic susceptibility testing does not help
the cardiologist decide on the most suitable antimicrobial
drug regimens. Another current concern is that we may be
returning to a time in which we are largely unable to suc-
cessfully treat simple infections from panresistant organ-
isms, a scenario that some have described as the
postantibiotic era. Indeed, in Northern Ireland, we have
now witnessed our first cases of penicillin-resistant pneu-
mococcal meningitis and endocarditis. The increasing inci-
dence of congenital heart disease in children and changing
social trends accentuate risk factors for endocarditis. 
Endothelial cell dysfunction, resulting from a combina-
tion of atypical mechanical forces due to altered cardiac
architecture and microbial infection, may lead to an
episode of infective endocarditis. Because the endothelium
helps regulate vascular tone, inflammation, thrombosis,
and vascular remodeling, any insult to the host endotheli-
um may result in infective endocarditis, in which the
valves may show changes in the synthetic, morphologic,
and metabolic functions of the valvular endothelial cells
(13).
Cases in Well-known Persons
Although a relatively uncommon infection, infective
endocarditis has been the primary cause of death of sever-
al well-known persons, particularly those involved with
the arts. One of the late 19th and early 20th century’s most
influential composers, Gustav Mahler (1860–1911), died
from streptococcal endocarditis (10,14). The first sign of
valvular problems was observed in 1907, where a compen-
sated mitral contraction was noted. For the next 3 years, he
showed little evidence of symptoms of valvular disease
until late 1910, when he spent Christmas and the New
Year’s holiday nursing a sore throat. He was in New York
City where he conducted a Philharmonic Orchestra concert
on January 17, including the first performance of a revised
version of his fourth symphony. On February 24, he
became ill with endocarditis, initially diagnosed as
influenza. He was attended by one of the most prominent
physicians in the city, Emanuel Libman, an important
exponent of the value of bacterial blood cultures. Libman
demonstrated the presence of viridans streptococci in a
large volume (200 mL) of blood drawn from Mahler.
Mahler’s initial treatment consisted of a “serum treatment”
of the times, as well as Metchnikoff’s Bulgarian Milk. The
latter treatment appeared to work, until early May when
blood cultures returned positive with viridans streptococci.
The endocarditis was now very marked, with septic
abscesses beginning to appear in other parts of his body.
On May 18, Mahler died. His untimely death prevented
society from hearing him conduct a completed version of
his tenth symphony as well as his own opportunity to hear
the first public performance of his ninth symphony, which
took place on June 26, 1912, by the Vienna Philharmonic
Orchestra.
Ottorino Respighi (1879–1936) was an Italian compos-
er who died at the age of 57 from endocarditis. The first
signs of Respighi’s endocarditis were noted in late 1935,
when he was working on his opera Lucrezia; at that time,
he was observed to be extremely fatigued, but the cause
was unknown (14). In January 1936, S. viridans endocardi-
tis was noted when this organism was isolated from his
blood. Although sulfonamide drugs were dispatched from
Berlin for his treatment, the treatment was unsuccessful,
possibly due to the advanced stages of sepsis. 
One of Scotland’s most famous poets, Roberts Burns
(1759–1796), perhaps best known for writing Auld Lang
Syne, also had infective endocarditis. He died in July 1796
at the age of 37 years (15). Some historians claim that
Burns’s work in his teenage years on his father’s tenant
farm in southwest Scotland did the primary damage to his
health. However, Burns’s history of rheumatic fever likely
predisposed him to infective endocarditis. Burns was
attended medically by William Maxwell (1760–1834),
who described Burns’s symptoms as “flying gout” and pre-
scribed sea-bathing in country quarters and horse riding,
so-called cures that probably hastened Burns’s death.
However, Burns’s affinity for alcohol may have con-
tributed to the suppression of his immune system, thus has-
tening the illness and ultimately his death. 
One of the most famous physicians to die of endocardi-
tis was Alois Alzheimer (1864–1915). Alzheimer is most
widely known for his description of an “unusual disease of
the cerebral cortex,” which affected a woman in her fifties,
causing memory loss, disorientation, hallucinations, and
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after him by his senior mentor at the Munich Medical
School, Emil Kraepelin. Alzheimer was also cofounder
and copublisher of the journal Zeitschrift für die gesamte
Neurologie und Psychiatrie. Alzheimer’s last position was
professor of psychiatry at the University of Breslau (now
Wroclaw, Poland), which he held for the last 3 years of his
life. Historians report that a severe cold was the beginning
of Alzheimer’s final illness, but endocarditis was responsi-
ble for his death at the age of 51 years (16). 
Orville Gibson, guitar manufacturer (1856–1918), was
another musician who died from endocarditis (17).
Gibson’s patent contained his ideas for the construction of
a mandolin with a carved top and back and with sides,
which were constructed from a solid section of wood
rather than from thin strips. In 1902, Gibson’s physical and
mental health began to fail, and he had a history of poor
health until 1911. He returned to the St. Lawrence State
Hospital, Ogdensburg, New York, in August 1916, a psy-
chiatric center. On August 21, 1918, Gibson died of endo-
carditis while a patient in the institution.
Rudolph Valentino (1895–1926), a famous actor of the
silent screen, also had endocarditis, which also led to his
death (18). Valentino had a perforated gastric ulcer closed
on August 15, 1926; however, he died from endocarditis
on August 23, 1926, at the age of 31 years. 
More recently, endocarditis has been described as the
cause of death for John Glascock (1951–1997), the record-
ing bass player with the rock band Jethro Tull. Glascock
had a tooth abscess, which was believed to be the site of
entry for an infectious agent that caused endocarditis.
Endocarditis developed in Brian Littrell (1975– ), singer
with the Backstreet Boys, at the age of 5 years (he was
born with a ventricular septal defect, although surgery was
not recommended at the time) (19). Brian was admitted to
St. Joseph’s Hospital, Lexington, Kentucky, where he
received extensive intravenous therapy. Endocarditis also
developed in a young American actor, Sebastian Hitzig,
after he accidentally stepped on a toothpick contaminated
with Staphylococcus aureus.
In conclusion, considering infective endocarditis to be
an “emerging” problem in the 21st century may seem
unusual, given that the illness has been well documented
over the last 450 years. However, such emergence can be
attributed to several factors: 1) the emergence of antimi-
crobial resistance in classic infective endocarditis
microflora, namely, the gram-positive cocci; 2) the exis-
tence of antimicrobial resistance in complex ecologic
biofilms; 3) the changing pattern of causal agents now
regarded as important pathogens of infective endocarditis,
e.g., Bartonella spp., T. whipplei, and fungi; and 4) chang-
ing epidemiologic trends of persons who acquire infective
endocarditis, including injection drug users, persons with
HIV/AIDS, children with congenital heart defects, and
persons undergoing body piercing. Furthermore, the way
we provide inpatient medical care has also been associated
with the emergence of nosocomial infective endocarditis,
which can result from invasive procedures such as
catheterization, although no cardiac surgery has been per-
formed. The next 100 years will likely witness the emer-
gence of even more changing trends of infective
endocarditis, which as yet have not been well recognized.
Although this “old” disease has evolved over the last
450 years, diagnostic and treatment options have devel-
oped in tandem, and the prognosis of this disease has
markedly improved. However, the emergence of novel eti-
ologic agents, changing social trends, and increased
antimicrobial resistance have allowed this disease to
remain evasive, which will require new approaches, partic-
ularly relating to treatment options in the future. 
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Appendix. Chronology of important scientific and medical events in the history of infective endocarditis
a 
Year  Scientist/physician, Country  Major findings 
1554  Jean François Fernel, France  Earliest report of endocarditis in book Medicini 
1669  Richard Lower,  England  Accurately described tricuspid valve endocarditis 
1646  Lazarus Riverius, France  Described unusual “outgrowths” from autopsy of patient with endocarditis; detected 
murmurs by placing hand on patient’s chest 
1708  Giovanni Maria Lancisi, Italy  Described unusual structures in entrance of aorta 
1715  Raymond Vieussens, France  Described abnormality in aortic mitral valve 
1749  Jean-Baptiste Sénac, France  Described valvular lesions 
1769  Giovanni Battistu Morgagni, 
Italy 
Linked infectious disease and endocarditis; observed association with the spleen 
1784  Eduard Sandifort, France  Accurately drew intracardiac abnormalities 
1797  Matthew Baillie, England  Showed relationship between rheumatism and heart disease 
1799  Xavier Bichat, France  Described inflammatory process associated with endocarditis 
1806  Jean Nicholas Corvisart, 
France 
Described unusual structures in heart as “vegetations,” syphilitic virus as causative agent 
of endocarditis, and theory of antiviral treatment of endocarditis 
1809  Allan Burns, England  Indicated vegetations were not “outgrowths” or “buds” but particles adhering to heart wall 
1815  Friedrich Kreysig, Germany  Elucidated inflammatory processes associated with endocarditis 
1816  Théophile Laënnec, France   Invented cylindrical stethoscope to listen to heart murmurs; dismissed link between 
venereal disease and endocarditis Infective Endocarditis
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Appendix continued. Chronology of important scientific and medical events in the history of infective endocarditis 
Year  Scientist/physician, Country  Major findings 
1832  James Hope, England  Confirmed Laënnec’s observations 
1835–40  Jean-Baptiste Bouillaud, 
France 
Named endocardium and endocarditis; described symptoms; prescribed herbal tea and 
bloodletting as treatment regimen; described link between acute rheumatoid arthritis and 
endocarditis 
1852  William Senhouse Kirkes, 
England 
Described consequences of embolization of vegetations throughout body. Described 
cutaneous nodules (named “Osler’s nodes” by Libman) 
1858–71  Rudolph Virchow, Germany  Examined fibrin vegetation associated with endocarditis by microscope; coined term 
“embolism;” discussed role of bacteria, vibrios, and micrococci in endocarditis 
1861  Jean-Martin Charot, France  Confirmed Virchow’s theory on emboli 
1861  Alfred Vulpian, Germany  Confirmed Virchow’s theory on emboli 
1862  Etienne Lancereaux, France  Described granulations or foreign elements in blood and valves, which were motile and 
resistant to alkalis 
1868–70  Samuel Wilks, England   Described infected arterial blood as originating from heart; proposed scarlet fever as 
cause of endocarditis 
1869  Emmanuel Winge, Norway  Established “parasites” on skin transported to heart and attached to endocardium; named 
“mycosis endocardii” 
1872  Hjalmar Heiberg, Norway  Detected microorganisms in vegetations of endocarditis 
1878  Edwin Klebs, Germany  All cases of endocarditis were infectious in origin 
1878  Ottomar Rosenbach, 
Germany/ 
Poland 
Combined experimental physiology and infection to produce animal model of endocarditis 
in rabbit; noted valve had to be damaged before bacteria grafted onto valve 
1878  Karl Koester, Germany  Micrococci enter vessels that valves were fitted into; valves exposed to abnormal 
mechanical attacks over long period created favorable niche for bacterial colonization 
1879  Joseph Hamburg, Germany  Virchow’s student; employed early animal model of endocarditis 
1879  Germain Sée, France  Proposed etiology of endocarditis was based on infectious model and treatment should 
focus on eliminating “parasitic infection” 
1880  Jacques Doleris, France  Working with Pasteur, proposed use of routine blood cultures  
1881–86  Arnold Netter, France   Believed endocarditis could appear during various infections; noted translocation of 
respiratory pathogen from pulmonary lesion to valve through blood 
1883  Michel Peter, France  Believed microorganisms were result, not cause, of endocarditis 
1884  Joseph Grancher, France  Named disease “infective endocarditis” 
1886  Valimir Wyssokowitsch and 
Johannes Orth, Germany 
Demonstrated various bacteria introduced to bloodstream could cause endocarditis on 
valve that had previous lesion 
1885  Sir William Osler, Canada  Synthesized work of others relating to endocarditis 
1899  Hermann Lenhartz, Austria  Described streptococcal, staphylococcal, pneumococcal, and gonococcal endocarditis 
1903  Hugo Schottmüller, Germany  First described “endocarditis lenta” 
1909  John Alexander Mullen, 
Canada 
Credited by Osler as first to observe cutaneous nodes (named “Osler’s nodes” by Libman) 
in patients with endocarditis 
1909  Sir Thomas Horder, England  Analyzed 150 cases of endocarditis and published diagnostic criteria relating to signs and 
symptoms 
1910  Emmanual Libman, USA  Described initial classification scheme to include “subacute endocarditis,” with clinical 
signs/symptoms; absolute diagnosis required blood cultures 
1981  Von Reyn, USA  Described Beth Israel criteria based on strict case definitions 
1994  David Durack, USA  New criteria utilizing specific echocardiographic findings  
1995  American Heart Association, 
USA 
Antibiotic treatment of adults with infective endocarditis caused by streptococci, 
enterococci, staphylococci, and HACEK
a microorganisms 
1996  Pierre Fournier, France  Modified Duke criteria to allow serologic diagnosis of Coxiella burnetii 
1997  American Heart Association, 
USA 
Guidelines for preventing bacterial endocarditis 
1997  Lamas and Eykyn, UK  Suggested modifications to Duke criteria for clinical diagnosis of native valve and 
prosthetic valve endocarditis: analysis of 118 pathologically proven cases 
1998  Working Party of the British 
Society for Antimicrobial 
Chemotherapy, UK 
Guidelines for antibiotic treatment of streptococcal, enterococcal, and staphylococcal 
endocarditis 
1998  Endocarditis Working Group 
of the International Society 
for Chemotherapy, Europe 
Antibiotic treatment of infective endocarditis due to viridans streptococci, enterococci, and 
other streptococci; recommendations for surgical treatment of endocarditis 
2000  Jennifer Li, USA  Updated and modified Duke criteria 
2002  Beverley C. Millar, UK  Modified Duke criteria to include a molecular diagnosis of causal agents (20) 
2001–
2003 
Didier Raoult, France  Described etiology of Bartonella spp., Tropheryma whipplei, and Coxiella burnetii in 
endocarditis 
aHACEK, Haemophilus aphrophilus, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella  corrodens, Kingella kingae group, 
Bartonella spp., and Coxiella burnetii. 
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